Abstract
Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)
| Original language | English |
|---|---|
| Pages (from-to) | 1067-1078 |
| Number of pages | 12 |
| Journal | Current Medical Research and Opinion |
| Volume | 27 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 2011 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
Cite this
Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy : A post hoc analysis. / Mohiuddin, Syed M.; Thakker, Kamlesh M.; Setze, Carolyn M.; Kelly, Maureen T.
In: Current Medical Research and Opinion, Vol. 27, No. 5, 05.2011, p. 1067-1078.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy
T2 - A post hoc analysis
AU - Mohiuddin, Syed M.
AU - Thakker, Kamlesh M.
AU - Setze, Carolyn M.
AU - Kelly, Maureen T.
PY - 2011/5
Y1 - 2011/5
N2 - Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)
AB - Objective: To evaluate the achievement of individual and combined lipid and lipoprotein/biomarker targets as specified by treatment guidelines with the combination of fenofibric acid and statin therapy in patients with mixed dyslipidemia. Methods: Data for the post hoc analyses were derived from three 12-week controlled studies and a 52-week extension study. Patients were treated with fenofibric acid 135 mg; low-, moderate-, or high-dose statin (rosuvastatin 10, 20, or 40 mg; atorvastatin 20, 40, or 80 mg; or simvastatin 20, 40, or 80 mg); or fenofibric acid + low- or moderate-dose statin in the controlled studies; and with fenofibric acid + moderate-dose statin in the extension study. Achievement of risk-stratified low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (ApoB) targets; and optimal levels of ApoB 40/50 mg/dL in men/women, triglycerides (TG)
UR - http://www.scopus.com/inward/record.url?scp=79954506700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79954506700&partnerID=8YFLogxK
U2 - 10.1185/03007995.2011.569018
DO - 10.1185/03007995.2011.569018
M3 - Article
VL - 27
SP - 1067
EP - 1078
JO - Current Medical Research and Opinion
JF - Current Medical Research and Opinion
SN - 0300-7995
IS - 5
ER -